Literature DB >> 29948828

Phylogenetic comparison of Epstein-Barr virus genomes.

Su Jin Choi1, Seok Won Jung1, Sora Huh1, Hyosun Cho2, Hyojeung Kang3.   

Abstract

Technologies used for genome analysis and whole genome sequencing are useful for us to understand genomic characterization and divergence. The Epstein-Barr virus (EBV) is an oncogenic virus that causes diverse diseases such as Burkitt's lymphoma (BL), nasopharyngeal carcinoma (NPC), Hodgkin's lymphoma (HL), and gastric carcinoma (GC). EBV genomes found in these diseases can be classified either by phases of EBV latency (type-I, -II, and -III latency) or types of EBNA2 sequence difference (type-I EBV, type-II EBV or EBV-1, EBV-2). EBV from EBV-transformed lymphoblastoid cell line (LCL) establishes type-III latency, EBV from NPC establishes type-II latency, and EBV from GC establishes type-I latency. However, other important factors play key roles in classifying numerous EBV strains because EBV genomes are highly diverse and not phylogenetically related to types of EBV-associated diseases. Herein, we first reviewed previous studies to describe molecular characteristics of EBV genomes. Then, using comparative and phylogenetic analyses, we phylogenetically analyzed molecular variations of EBV genomes and proteins. The review of previous studies and our phylogenetic analysis showed that EBV genomes and proteins were highly diverse regardless of types of EBV-associated diseases. Other factors should be considered in determining EBV taxonomy. This review will be helpful to understand complicated phylogenetic relationships of EBV genomes.

Entities:  

Keywords:  Epstein-Barr virus; genomic variations; phylogenetic analysis

Mesh:

Substances:

Year:  2018        PMID: 29948828     DOI: 10.1007/s12275-018-8039-x

Source DB:  PubMed          Journal:  J Microbiol        ISSN: 1225-8873            Impact factor:   3.422


  47 in total

1.  MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods.

Authors:  Koichiro Tamura; Daniel Peterson; Nicholas Peterson; Glen Stecher; Masatoshi Nei; Sudhir Kumar
Journal:  Mol Biol Evol       Date:  2011-05-04       Impact factor: 16.240

Review 2.  Progress and problems in understanding and managing primary Epstein-Barr virus infections.

Authors:  Oludare A Odumade; Kristin A Hogquist; Henry H Balfour
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

3.  An Epstein-Barr virus isolated from a lymphoblastoid cell line has a 16-kilobase-pair deletion which includes gp350 and the Epstein-Barr virus nuclear antigen 3A.

Authors:  W Lee; Y H Hwang; S K Lee; C Subramanian; E S Robertson
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

4.  Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes.

Authors:  J Sample; L Young; B Martin; T Chatman; E Kieff; A Rickinson; E Kieff
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

5.  Whole-genome sequencing of the Akata and Mutu Epstein-Barr virus strains.

Authors:  Zhen Lin; Xia Wang; Michael J Strong; Monica Concha; Melody Baddoo; Guorong Xu; Carl Baribault; Claire Fewell; William Hulme; Dale Hedges; Christopher M Taylor; Erik K Flemington
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

6.  The full-length DNA sequence of Epstein Barr virus from a human gastric carcinoma cell line, SNU-719.

Authors:  Kyung-A Song; San-Duk Yang; Jinha Hwang; Jong-Il Kim; Myung-Soo Kang
Journal:  Virus Genes       Date:  2015-10-12       Impact factor: 2.332

7.  Characterization of naturally Epstein-Barr virus-infected gastric carcinoma cell line YCCEL1.

Authors:  Do Nyun Kim; Min Koo Seo; Hoyun Choi; Su Yeon Kim; Hee Jong Shin; A-Ran Yoon; Qian Tao; Sun Young Rha; Suk Kyeong Lee
Journal:  J Gen Virol       Date:  2012-11-21       Impact factor: 3.891

8.  Epstein-barr virus, the immune system, and associated diseases.

Authors:  Mei-Ru Chen
Journal:  Front Microbiol       Date:  2011-01-26       Impact factor: 5.640

9.  A novel persistence associated EBV miRNA expression profile is disrupted in neoplasia.

Authors:  Jin Qiu; Katherine Cosmopoulos; Michiel Pegtel; Erik Hopmans; Paul Murray; Jaap Middeldorp; Michael Shapiro; David A Thorley-Lawson
Journal:  PLoS Pathog       Date:  2011-08-25       Impact factor: 6.823

10.  Genome-wide Analysis of Epstein-Barr Virus (EBV) Integration and Strain in C666-1 and Raji Cells.

Authors:  Kai Xiao; Zhengyuan Yu; Xiayu Li; Xiaoling Li; Ke Tang; Chaofeng Tu; Peng Qi; Qianjin Liao; Pan Chen; Zhaoyang Zeng; Guiyuan Li; Wei Xiong
Journal:  J Cancer       Date:  2016-01-01       Impact factor: 4.207

View more
  6 in total

Review 1.  Interplay between Epstein-Barr virus infection and environmental xenobiotic exposure in cancer.

Authors:  Francisco Aguayo; Enrique Boccardo; Alejandro Corvalán; Gloria M Calaf; Rancés Blanco
Journal:  Infect Agent Cancer       Date:  2021-06-30       Impact factor: 2.965

Review 2.  Epstein-Barr virus strain variation and cancer.

Authors:  Teru Kanda; Misako Yajima; Kazufumi Ikuta
Journal:  Cancer Sci       Date:  2019-02-21       Impact factor: 6.716

3.  A reliable Epstein-Barr Virus classification based on phylogenomic and population analyses.

Authors:  Louise Zanella; Ismael Riquelme; Kurt Buchegger; Michel Abanto; Carmen Ili; Priscilla Brebi
Journal:  Sci Rep       Date:  2019-07-08       Impact factor: 4.379

4.  F factor plasmid-mediated Epstein-Barr virus genome introduction establishes an EBV positive NPC cell model.

Authors:  Jingling Duan; Yang Yang; Zhen Wu; Shiang Lin; Chen Zhou; Guowen Sheng; Fan Yang; Lihui Bian; Xiaoling Zhang; Shengjun Xiao
Journal:  Cancer Manag Res       Date:  2019-08-05       Impact factor: 3.989

Review 5.  Stress-Induced Epstein-Barr Virus Reactivation.

Authors:  Daniel G Sausen; Maimoona S Bhutta; Elisa S Gallo; Harel Dahari; Ronen Borenstein
Journal:  Biomolecules       Date:  2021-09-18

Review 6.  Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer.

Authors:  Ramon Yarza; Mateo Bover; Maria Teresa Agulló-Ortuño; Lara Carmen Iglesias-Docampo
Journal:  J Exp Clin Cancer Res       Date:  2021-06-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.